Targets › CHCHD10
1 program from 1 company in 2 trials: 2 Phase 1; Neurology; next expected readout Apr 2027.
May be involved in the maintenance of mitochondrial organization and mitochondrial cristae structure. (UniProt, Q8WYQ3)
Open in Phaseline: the race on CHCHD10, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| n-Lorem Foundation | nL-CHCHD-001 Antisense oligonucleotide targeting CHCHD10 | CHCHD10 | Phase 1 | Amyotrophic Lateral Sclerosis | Apr 2027 |
Amyotrophic Lateral Sclerosis (2)
small molecule (1)
n-Lorem Foundation (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.